Dr. Reddy’s Laboratories along with its subsidiaries has terminated the license granted to Armis Biopharma (formerly known as CHO Bioscience) for its investigational antibacterial product, DFA-02, for the prophylaxis of surgical site infections (SSIs). As a result of the termination, the company has regained worldwide rights to DFA-02, and is currently evaluating its options to take the program forward.
DFA-02 is a combination, broad spectrum antibacterial in situ gel which is being investigated for the prophylaxis of SSIs as an adjunct to conventional preoperative antibiotic prophylaxis. DFA-02 has been studied in several phase 1 and 2 clinical studies, and has demonstrated clinical efficacy in several key segments of patients who were at high risk for SSIs.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: